Taiho Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.taihooncology.com
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
- Conditions
- Interventions
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04093362
- Locations
- 🇳🇱
Radboud University Medical Center, Nijmegen, GA, Netherlands
🇺🇸Utah Cancer Specialists, Salt Lake City, Utah, United States
🇰🇷Asan Medical Center, Seul, Seoul, Korea, Republic of
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Conditions
- Interventions
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT04093570
- Locations
- 🇺🇸
Hackensack Medical Center - 06 FE Study, Hackensack, New Jersey, United States
🇦🇹Wiener Gesundheitsverbund - Klinik Hietzing 06 FE Study, Vienna, Austria
🇦🇹Wiener Gesundheitsverbund - Klinik Hietzing 06 Study, Vienna, Austria
A Study of TAS-120 in Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT04024436
- Locations
- 🇺🇸
BIDMC, Boston, Massachusetts, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸USCF, San Francisco, California, United States
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT03975387
- Locations
- 🇺🇸
Columbia University Irving Medical Center - Herbert Irving Pavilion Site#104, New York, New York, United States
🇺🇸Cedars-Sinai Medical Center Site #105, Los Angeles, California, United States
🇺🇸City of Hope Comprehensive Cancer Center Site#114, Duarte, California, United States
Study of ASTX029 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT03520075
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of Southern California Norris Comprehensive Cancer Center Site#114, Los Angeles, California, United States
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
- Conditions
- Interventions
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT03502668
- Locations
- 🇺🇸
Indiana University Health Hospital - Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities
- Conditions
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03410927
- Locations
- 🇺🇸
University of Texas - MD Anderson, Houston, Texas, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
The CHOICE Registry
- Conditions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03148093
- Locations
- 🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02978235
- Locations
- 🇺🇸
Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
A Study of TAS-116 in Patients With Solid Tumors
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02965885
- Locations
- 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇮🇹Regina Elena National Cancer Institute, Roma, Italy
🇬🇧The Christie NHS Foundation Trust Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom